Skip to main content

Table 4 Resistance rates of isolated pathogens

From: Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single center experience in Serbia

ABs

Enterococcus spp b

Enterobacteriaceae

Totala

P value

Overall

MDR (n = 12)

Non-MDR (n = 22)

MDR (n = 18)

Non-MDR (n = 4)

MDR (n = 35)

Non-MDR (n = 30)

n = 65

AMP

8/11 (72.7)

2/20 (10.0)

16/18(88.9)

4/4 (100)

29/34(85.3)

10/28 (35.7)

0.000

39/62 (62.9)

AMX

8/11 (72.7)

2/20 (10.0)

16/18(88.9)

4/4 (100)

29/34 (85.3)

9/27 (33.3)

0.000

38/61 (62.3)

AMP-SL

1/2 (50.0)

1/6 (50.0)

16/18(88.9)

4/4 (100)

8/12 (66.7)

3/8 (37.5)

0.362

11/20 (55.0)

AM-CL

7/9 (77.8)

2/14 (14.3)

16/18(88.9)

2/4 (50.0)

26/30(86.7)

7/22 (31.8)

0.000

33/52 (63.5)

P-TZ

2/2 (100)

0/2 (0)

5/13 (38.5)

1/3 (33.3)

9/17 (52.9)

1/7 (14.3)

0.172

10/24 (41.7)

MER

4/5 (80.0)

0/4 (0)

6/15 (40.0)

1/3 (33.3)

14/24(58.3)

1/9 (11.1)

0.021

15/33 (45.4)

IMI

6/7 (85.7)

1/6 (16.7)

5/13 (38.5)

0/3 (0)

16/25(64.0)

1/11 (9.1)

0.003

17/36(47.2)

ERT

4/4 (100)

0/4 (0)

8/13 (61.5)

1/2 (50.0)

17/22(77.3)

3/8 (37.5)

0.078

20/30 (66.7)

CFAZ

–

–

16/16 (100)

1/3 (33.3)

32/32 (100)

20/23 (86.9)

0.068

52/55 (94.5)

CEPH

–

–

18/18 (100)

1/4 (25.0)

35/35 (100)

21/25 (84.0)

0.026

56/60 (93.3)

CEFU

–

–

16/16 (100)

1/4 (25.0)

32/32 (100)

21/26 (80.8)

0.014

53/58 (91.4)

CEFO

–

–

16/17(94.1)

1/4 (25.0)

32/33(97.0)

21/25 (84.0)

0.154

53/58 (91.4)

CFTX

–

–

17/17 (100)

1/4 (25.0)

33/33 (100)

21/25 (84.0)

0.030

54/58 (93.1)

CFTA

–

–

18/18 (100)

1/3 (33.3)

33/34(97.0)

20/24 (83.3)

0.004

53/58 (91.4)

CEFP

–

–

18/18 (100)

1/4 (25.0)

33/34(97.0)

20/24 (83.3)

0.149

53/58 (91.4)

AMI

1/1 (100)

1/3 (33.3)

4/16 (25.0)

1/3 (33.3)

8/20 (40.0)

2/10 (20.0)

0.419

10/30 (33.3)

GEN

4/8 (50.0)

3/6 (50.0)

7/13 (53.8)

1/4 (25.0)

14/25(56.0)

4/12 (33.3)

0.295

18/37 (48.6)

CIP

11/11(100)

12/13 (92.3)

10/13(76.9)

1/4 (25.0)

23/26(88.5)

13/19 (68.4)

0.137

36/45 (80.0)

LEVO

1/1 (100)

2/2 (100)

3/3 (100)

1/3 (33.3)

5/5 (100)

3/7 (42.8)

0.081

8/12 (66.7)

VAN

5/12 (41.7)

2/21 (9.5)

1/5 (20.0)

1/1 (100)

7/20 (35.0)

3/23 (13.0)

0.148

10/43 (23.2)

TEI

7/12 (58.3)

1/21 (4.8)

1/5 (20.0)

1/1 (100)

10/19(52.6)

2/22 (9.1)

0.005

12/41 (29.3)

T-SX

1/2 (50.0)

2/4 (50.0)

1/5 (20.0)

1/1 (100)

19/24(79.2)

7/11 (63.6)

0.416

26/35 (74.3)

NIF

6/8 (75.0)

2/6 (33.3)

5/5 (100)

1/2 (50.0)

11/15(73.3)

3/8 (37.5)

0.179

14/23 (60.9)

LIN

1/4 (25.0)

0/5 (0)

1/7 (14.3)

1/1 (100)

1/7 (14.3)

1/7 (14.3)

1.000

2/14 (14.3)

TIG

1/3 (33.3)

0/3 (0)

0/1 (0)

1/2 (50.0)

1/6 (16.7)

1/5 (20.0)

1.000

2/11 (18.2)

  1. Notes: This table shows the resistance rates to most commonly used antibiotics in clinical practice with comparison between MDR and non MDR pathogens. b due to the intrinsic cephalosporin resistance, data are not shown for enterococci but are included in totals and the overall analysis. aAcinetobacter baumanii, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus included in analysis but not shown. ABs stands for antibiotics; AMP Ampicillin, AMX Amoxicillin, AMP-SL Ampicillin sulbactam, AM-CL Amoxicillin-clavulanic acid, P-TZ Piperacillin-tazobactam, MER Meropenem, IMI Imipenem, ERT Ertapenem, CFAZ Cefazolin, CEPH Cephalexin, CEFU Cefuroxime, CEFO Cefotaxime, CFTX Ceftriaxone, CFTA Ceftazidime, CEFP Cefepime, AMI Amikacin, GEN Gentamicin, CIP Ciprofloxacin, LEVO Levofloxacin, VAN Vancomycin, TEI Teicoplanin, T-SX Trimethoprim-sulfamethoxazole, NIF Nitrofurantoin, LIN Linezolid, and TIG Tigecycline
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us